Latest Breaking News On - Roland chen - Page 2 : vimarsana.com

Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies

Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain...

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

BMS' Zeposia comes up short in Crohn's disease study

Bristol-Myers Squibb (BMY) Provides Update on the First Phase 3 YELLOWSTONE Trial of Oral Zeposia

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease -March 28, 2024 at 04:02 pm EDT

Bristol Myers Squibb today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia ...

Bristol Myers Squibb to Present Data at on CAMZYOS (mavacamten) for obstructive hypertrophic cardiomyopathy (HCM) at American College of Cardiology Annual Scientific Session, ACC.24

Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.

Washington State University: Recipients of Commercialization Gap Funding Awards Announced

The Office of Commercialization has awarded eight WSU researchers with the Commercialization Gap Fund (CGF). The CGF supports research projects with high market potential and provides researchers up to $50,000 to demonstrate their innovation(s) can m

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio

Analysis from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF ...

Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023

New clinical analyses and real-world data continue to demonstrate the benefit of treatment with CAMZYOS (mavacamten) for patients with symptomatic obstructive HCM 

FDA Grants Breakthrough Therapy Designation to Novel Drug for Progressive Pulmonary Fibrosis

BMS-986278 (Bristol Myers Squibb) is a potential first-in-class treatment for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.